Erasca, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ERAS | 9966.HK | RVMD | 2256.HK | IDYA | RLAY | |
|---|---|---|---|---|---|---|
| Market cap | 5.21B | 6.43B | 42.80B | 5.03B | 3.12B | 3.95B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -23.9 | -21.0 | -34.6 | -24.1 | -7.9 | -11.0 |
| Price/book | 12.9 | 3.3 | 24.1 | 2.0 | 2.9 | 5.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +565.63% | −39.84% | +225.35% | −54.94% | +8.41% | +176.11% |
| Today | +1.84% | +1.68% | +2.82% | +6.85% | +3.29% | +3.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ERAS news ›Tango and Erasca launch Phase 1/2 trial combining vopimetostat and ERAS-0015 for pancreatic and lung cancers
Tango Therapeutics and Erasca have started a Phase 1/2 clinical trial testing the combination of oral PRMT5 inhibitor vopimetostat with pan-RAS molecular glue ERAS-0015. The trial targets patients with MTAP-deleted pancreatic ductal…
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 GlobeNewswire
Erasca, Inc. (NASDAQ:ERAS) Stock Now Rated “Moderate Buy” by Wall Street Brokerages
Posted by Michael Walen on Oct 28th, 2026 Get Our Latest Research Report on Erasca NASDAQ ERAS opened at $15.22 on Wednesday. Erasca has a fifty-two week low of $2.11 and a fifty-two week high of $24.28. The stock’s 50-day moving average…
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf
October 21, 2026 08:24 ET | Source: Grabar Law Office Follow Grabar Law Office PHILADELPHIA , Oct. 21, 2026 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders…
Erasca drops after sacking COO
Erasca (ERAS) stock dips as the employment of chief operating officer is terminated as part of a leadership realignment initiative. Read more here. - Erasca (ERAS) shares fell on Friday after the cancer drug developer terminated the…
Erasca Foundation proposes $122K share sale
An 8,333-share Erasca (ERAS) sale is proposed by Erasca Foundation, with shares valued at $122K. Stock Titan Erasca Foundation proposes $122K share sale The notice traces the foundation's common shares to a 10,193,557-share donation from…
Discontinued operations of PROLOGUE SA – GETTEX:A42KN6
Prologue SA engages in the provision of Cloud, IP Communications, Enterprise Content Management and Exchange solutions. It provides consulting, installation, projects management assistance and technical assistance services. The company's…
Important Notice to Long-Term Shareholders of American Express Company (NYSE: AXP); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS) and Planet Fitness, Inc. (NYSE: PLNT): Grabar Law Office is Investigating Claims on Your Behalf
PHILADELPHIA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- American Express Company (NYSE: AXP): What is Happening? Grabar Law Office is investigating claims on behalf of long-term shareholders of American Express Company (NYSE: AXP). What is the…
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (ERAS), DICK’S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR)
Erasca, Inc. (NASDAQ: ERAS) DICK’S Sporting Goods, Inc. (NYSE: DKS) If you purchased DICK’S Sporting Goods shares before May 25, 2022, and have continuously held those shares, you may have standing to seek corporate governance reforms at…
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
Propanc believes these mechanisms address residual drivers of resistance, dormancy, and metastasis that can persist after RAS pathway blockade – creating a scientific rationale for combination or sequential use with RAS inhibitors. A…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- globenewswire.com4
- seekingalpha.com2
- themarketsdaily.com2
- tradingview.com2
- markets.businessinsider.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 15 articles, not a forecast.